AT2604 / Axcynsis Therap - LARVOL DELTA

AT2604 is a highly efficacious ADC targeting alkaline phosphatases ALPP and ALPPL2​ (AACR 2025) - "In patient-derived xenograft models of gastric cancer with moderate- and low-antigen expression, AT2604 achieves near-complete tumor regression at 3 and 6 mg/kg (QWx3), respectively. A preliminary toxicity assessment in non-human primates concluded a well-tolerated dose of 10 mg/kg (Q3Wx3) without exhibiting any non-reversible adverse effects.and good plasma stability; implying that AT2604 possesses an improved safety profile over other vedotin-based ADCs."

Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • ALPP

Development of AT2604, a highly efficacious ADC targeting alkaline phosphatases ALPP and ALPPL2​ (AACR 2024) - "Furthermore, a pre-tox study in non-human primates concluded AT2604 has a HNSTD of 10 mg/kg (QW3x3 dosing) and did not exhibit any non-reversible adverse effects; implying that AT2604 possesses an improved safety profile over other vedotin-based ADCs. Taken together, the data supports the continued development of AT2604 towards evaluation in human trials.​"

Oncology • Pancreatic Cancer • ALPP